GPC Biotech Presents New Satraplatin Pre-clinical Data at AACR.

(From Hugin)

Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- - Therapeutic synergism in vivo when satraplatin is combined with Taxotere (docetaxel) in non-small cell lung cancer model - Strong synergistic effect when satraplatin's active metabolite, JM-118, is combined with Herceptin (trastuzumab) in breast cancer cells

Martinsried/Munich (Germany) and Waltham, Mass. and Princeton, N.J., April 3, 2006 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced the presentation of new pre-clinical data on its lead drug candidate satraplatin at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC. "The data presented at AACR are supportive of the clinical work we have underway to explore the potential of satraplatin in a variety of combination therapies and cancer settings," said Marcel Rozencweig, M.D., Senior Vice President, Drug Development. "We currently have ongoing two Phase 1 trials evaluating satraplatin in combination with Taxotere in advanced solid tumors. We also have underway a Phase 2 study evaluating satraplatin in metastatic breast cancer, and we expect to further explore satraplatin in this treatment setting in …